基于尿液的良性前列腺增生进展的非侵入式预测试剂盒与方法
By detecting the concentration of FGF9 protein in urine, a non-invasive method for predicting the progression of benign prostatic hyperplasia (BPH) using an ELISA kit is provided, which solves the problem of insufficient invasive diagnosis and prediction in existing technologies and achieves efficient and accurate prediction of BPH progression.
CN117074660BActive Publication Date: 2026-07-17ZHONGSHAN HOSPITAL FUDAN UNIV
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- ZHONGSHAN HOSPITAL FUDAN UNIV
- Filing Date
- 2023-05-26
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
Current diagnostic methods for the progression of benign prostatic hyperplasia (BPH) mainly rely on invasive approaches, which impose a physical and economic burden on patients. Furthermore, existing technologies cannot effectively predict the effectiveness of drug treatment, and some patients cannot avoid surgical intervention.
Method used
Using FGF9 as a biomarker in urine, the concentration of FGF9 protein in urine is detected by an ELISA kit, providing a non-invasive predictive method to determine whether a patient will experience symptom progression.
Benefits of technology
It achieves non-invasive, accurate, simple and practical prediction of BPH progression, reducing patient suffering and economic burden, and improving the accuracy and reliability of prediction.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN117074660B_ABST
Abstract
本发明涉及基于尿液的良性前列腺增生进展的非侵入式预测试剂盒与方法。本发明提供FGF9作为基于尿液的良性前列腺增生进展的非侵入式预测生物标志物的应用，所述FGF9在尿液中浓度作为判断良性前列腺增生进展的指标。本发明还提供了非疾病诊断目的的检测尿液中FGF9浓度的方法。与现有技术相比，本发明基于尿液的BPH非侵入式检测方法，具有非侵入性、精准性、简便性、实用性和可扩展性等优点，有望在前列腺疾病的临床诊断和治疗中得到广泛应用。
Need to check novelty before this filing date? Find Prior Art